Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBITDA Margin (2019 - 2025)

BridgeBio Pharma's EBITDA Margin history spans 7 years, with the latest figure at 90.52% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 375217.0% year-over-year to 90.52%; the TTM value through Dec 2025 reached 104.25%, up 16297.0%, while the annual FY2025 figure was 104.25%, 16297.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 90.52% at BridgeBio Pharma, up from 120.3% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 19953.49% in Q4 2021 and bottomed at 38200.0% in Q3 2022.
  • The 5-year median for EBITDA Margin is 5116.28% (2023), against an average of 6423.63%.
  • The largest YoY upside for EBITDA Margin was 12445267bps in 2021 against a maximum downside of -3881206bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 19953.49% in 2021, then tumbled by -135bps to 6910.8% in 2022, then crashed by -47bps to 10167.11% in 2023, then soared by 62bps to 3842.69% in 2024, then skyrocketed by 98bps to 90.52% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's EBITDA Margin are 90.52% (Q4 2025), 120.3% (Q3 2025), and 121.45% (Q2 2025).